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Background
The combination of stavudine (d4T), 3TC and NVP was
the WHO recommended first-line regimen for the treat-
ment of naïve HIV-1 infected patients in resource-limited
settings. But peripheral polyneuropathy, lipoatrophy and
symptomatic hyperlactatemia are frequent and treatment-
limiting adverse events associated with stavudine, espe-
cially when combined with antituberculous drugs. Teno-
fovir combined with lamivudine and efavirenz has proven
excellent efficacy, but there is little experience when given
with NVP.
Methods
Retrospective analysis of all patients receiving TDF, NVP
and 3TC or FTC as first-line treatment in the Frankfurt HIV
cohort.
Summary of results
70 patients (15 female) with a median CD4 cell count of
210/μl (47–949) and HIV-RNA PCR of 140,000 copies/
ml (2,500–2,000,000) at baseline received TDF, NVP and
3TC/FTC, and were treated for a median of 68 weeks (16–
278). CD4 cells rose up to cells/μl 322 (119–1075) and
75% of the patients remained on treatment. All patients
on treatment at week 48 were <50 c/ml, even those start-
ing with CD4 cells of <200 cells/μl or a HIV-RNA PCR
>100,000 c/m. Reasons for discontinuation (24%) were
mainly adverse events (13%), with rash (7%) and liver
toxicity (6%) being the two most common, whereas viro-
logic failure, drug interaction and non-adherence were all
relatively rare (each 3%).
Conclusion
The combination of NVP, TDF and 3TC or FTC is effective
and well tolerated in previously naïve HIV-1 infected
patients even when started with low CD4 cell counts
(<200/ml) and high viral loads (>100,000 c/ml). In the
latest amendment of the WHO guidelines TDF, instead of
d4T, is the recommended first-line treatment in resource-
limited settings.
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